Prevention of experimental atherosclerosis, aneurysm and heart failure bydeletion of TLR4 was previously reported, suggesting that TLR4 may represent anovel therapeutic target for pharmacological treatment of CVD.8 Having shown that FP7 can negatively regulate mouse TLR4 signalling, inthe next series of experiments we tested the efficacy of FP7 to modulatein vivo vascular TLR4 signalling pathways. This evidence concerns the gene TLR4 and atherosclerosis.